New Memorial Sloan Kettering research demonstrates the powerful clinical benefit of giving patients a drug that targets the molecular abnormality driving the growth of a rare and debilitating joint disease.

View article:
Study Suggests Targeted Drug Is a Potential Therapy for Rare Joint Disorder PVNS